Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Disease

ClinicalTrials.gov lists 2,494 trials for Disease or a narrower condition beneath it. Institut National de la Santé Et de la Recherche Médicale, France has the most among industry and government lead sponsors, with 9.

MeSH D004194 Pathological Conditions, Signs and Symptoms C23 Listed by Orphanet as a rare disease
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 76 Phase 1/2 Phase 1/2 31 Phase 2 Phase 2 107 Phase 2/3 Phase 2/3 18 Phase 3 Phase 3 86 Phase 4 Phase 4 72 Not applicable Not applicable 905 Observational Observational 1,193 Phase 1 Phase 1 76 Phase 1/2 Phase 1/2 31 Phase 2 Phase 2 107 Phase 2/3 Phase 2/3 18 Phase 3 Phase 3 86 Phase 4 Phase 4 72 Not applicable Not applicable 905 Observational Observational 1,193

Trials per phase (log scale)

2 more sections with rows

2,385 of the 2,494 trials are tagged with Disease itself; the rest are tagged with a narrower condition beneath it.

Get the Disease report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Disease trials start? (33)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 7 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Expanded access, Unknown)

Top of scale: 247

1992: 1 trials (Phase 2 1) 1993: 1 trials (Observational 1) 1996: 2 trials (Observational 2) 1997: 1 trials (Observational 1) 1998: 4 trials (Observational 3, Phase 3 1) 1999: 2 trials (Observational 2) 2000: 4 trials (Observational 4) 2001: 7 trials (Observational 1, Phase 3 4, Phase 2 2) 2002: 6 trials (Observational 2, Not applicable 1, Phase 3 3) 2003: 15 trials (Observational 6, Not applicable 4, Phase 4 1, Phase 3 1, Phase 2 3) 2004: 19 trials (Observational 5, Not applicable 4, Phase 4 2, Phase 3 5, Phase 2 3) 2005: 25 trials (Observational 9, Not applicable 4, Phase 4 3, Phase 3 6, Phase 2 2, Phase 1/2 1) 2006: 26 trials (Observational 11, Not applicable 4, Phase 4 2, Phase 3 3, Phase 2 3, Phase 1/2 1, Phase 1 2) 2007: 38 trials (Observational 13, Not applicable 11, Phase 4 4, Phase 3 2, Phase 2 4, Phase 1/2 1, Phase 1 3) 2008: 50 trials (Observational 19, Not applicable 16, Phase 4 2, Phase 3 3, Phase 2 5, Phase 1/2 1, Phase 1 4) 2009: 62 trials (Observational 34, Not applicable 14, Phase 4 1, Phase 3 6, Phase 2/3 2, Phase 2 4, Phase 1/2 1) 2010: 52 trials (Observational 26, Not applicable 12, Phase 4 3, Phase 3 4, Phase 2 4, Phase 1 3) 2011: 51 trials (Observational 26, Not applicable 19, Phase 4 2, Phase 2 1, Phase 1/2 1, Phase 1 2) 2012: 59 trials (Observational 22, Not applicable 22, Phase 4 5, Phase 3 3, Phase 2/3 1, Phase 2 3, Phase 1/2 1, Phase 1 2) 2013: 62 trials (Observational 31, Not applicable 24, Phase 4 4, Phase 1/2 3) 2014: 83 trials (Observational 31, Not applicable 33, Phase 4 3, Phase 3 5, Phase 2/3 1, Phase 2 4, Phase 1/2 2, Phase 1 4) 2015: 91 trials (Observational 45, Not applicable 37, Phase 4 1, Phase 3 4, Phase 2/3 2, Phase 1 2) 2016: 99 trials (Other 1, Observational 49, Not applicable 36, Phase 4 1, Phase 3 2, Phase 2/3 2, Phase 2 4, Phase 1/2 1, Phase 1 3) 2017: 135 trials (Observational 66, Not applicable 51, Phase 4 3, Phase 3 2, Phase 2/3 1, Phase 2 5, Phase 1/2 2, Phase 1 5) 2018: 105 trials (Other 1, Observational 53, Not applicable 37, Phase 4 2, Phase 3 2, Phase 2/3 1, Phase 2 4, Phase 1/2 1, Phase 1 4) 2019: 133 trials (Observational 57, Not applicable 54, Phase 4 4, Phase 3 5, Phase 2/3 1, Phase 2 7, Phase 1/2 1, Phase 1 4) 2020: 135 trials (Observational 67, Not applicable 47, Phase 4 2, Phase 3 4, Phase 2/3 3, Phase 2 7, Phase 1/2 1, Phase 1 4) 2021: 167 trials (Observational 96, Not applicable 58, Phase 4 1, Phase 3 3, Phase 2 4, Phase 1 5) 2022: 162 trials (Observational 82, Not applicable 63, Phase 4 4, Phase 3 3, Phase 2 4, Phase 1/2 4, Phase 1 2) 2023: 201 trials (Observational 103, Not applicable 75, Phase 4 5, Phase 3 3, Phase 2 6, Phase 1/2 2, Phase 1 7) 2024: 184 trials (Observational 101, Not applicable 64, Phase 4 6, Phase 3 3, Phase 2/3 2, Phase 2 4, Phase 1 4) 2025: 247 trials (Observational 119, Not applicable 100, Phase 4 3, Phase 3 2, Phase 2/3 1, Phase 2 11, Phase 1/2 4, Phase 1 7)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 245
2025 247
2024 184
2023 201
2022 162
2021 167
2020 135
2019 133
2018 105
2017 135

Showing 10 of 33 earlier years.

Start your 14-day trial Email me all 33 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 280 trials starting in 2026 and about 260 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 163 trials still running at the 2026-10-09 snapshot; registered median of 19 months across 1,232 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Disease trials in? (10)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 76
Phase 1/2 31
Phase 2 107
Phase 2/3 18
Phase 3 86
Phase 4 72
Not applicable 905
Observational 1,193
Expanded access 5
Unknown 1

How many Disease trials are recruiting? (12)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 197
Recruiting 448
Enrolling by invitation 43
Active, not recruiting 79
Available 2

Showing 5 of 12 statuses.

Start your 14-day trial Email me all 12 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Disease trials? (1)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Institut National de la Santé Et de la Recherche Médicale, France 9

Which drugs are being tested for Disease? (2)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Cytoxan 7
18F-FDG 5

Interventions as named in the registry (13)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Dexamethasone/Dexamethasone acetate 13
MRI 10
Blood Sampling 10
Exercise 7
No Interventions 6

Showing 5 of 13 interventions.

Start your 14-day trial Email me all 13 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Disease trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Graft versus host disease 74 1
PNEUMONIA 72 1
ATRIAL FIBRILLATION 68 1
CORONARY ARTERY DISEASE 68 1
Pneumonia 63 14

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Disease? (307)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Realistic expectations are key to realising the benefits of polygenic scores. BMJ (Clinical research ed.) 2023 Yes
Organ aging signatures in the plasma proteome track health and disease. Nature 2023 Yes
Untargeted sequencing of circulating microRNAs in a healthy and diseased older population. Scientific reports 2022 Yes
Circadian rhythm and disease: Relationship, new insights, and future perspectives. Journal of cellular physiology 2022 Yes
Fibroblasts: Origins, definitions, and functions in health and disease. Cell 2021 Yes

Showing 5 of 307 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (1)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages